This is an aggregated industry headline. Read the full story at BioPharma Dive →
Alkermes' incoming CEO has a plan to outplay Lilly and Takeda
Blair Jackson says the next 12 months may be the most important in Alkermes' history, as the brain drugmaker races to join an "orexin" market that analysts see as a multibillion-dollar opportunity.
By BioPharma Dive
· Jun 26, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
As Amgen prepares to defend Tavneos' market approval in the U.S., the company has received a bad omen overseas…
The WeekFierceBiotech ↗
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case f…
The WeekBriefing
STAT News flagged two developments: a congressional bill to revamp the 340B drug discount program and talk of …